Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Aug;20(8):754-8.
doi: 10.1111/j.1525-1497.2005.0161.x.

Barriers to the treatment of hepatitis C. Patient, provider, and system factors

James A Morrill  1 , Melissa Shrestha, Richard W Grant
Affiliations

Barriers to the treatment of hepatitis C. Patient, provider, and system factors

James A Morrill et al. J Gen Intern Med. 2005 Aug.

Abstract

Background: Hepatitis C virus (HCV) infection is both prevalent and undertreated.

Objective: To identify barriers to HCV treatment in primary care practice.

Design: Cross-sectional study.

Setting and participants: A cohort of 208 HCV-infected patients under the care of a primary care physician (PCP) between December 2001 and April 2004 at a single academically affiliated community health center.

Measurements: Data were collected from the electronic medical record (EMR), the hospital clinical data repository, and interviews with PCPs.

Main results: Our cohort consisted of 208 viremic patients with HCV infection. The mean age was 47.6 (+/-9.7) years, 56% were male, and 79% were white. Fifty-seven patients (27.4% of the cohort) had undergone HCV treatment. Independent predictors of not being treated included: unmarried status (adjusted odds ratio [aOR] for treatment 0.36, P=.02), female gender (aOR 0.31, P=.01), current alcohol abuse (aOR 0.08, P=.0008), and a higher ratio of no-shows to total visits (aOR 0.005 per change of 1.0 in the ratio of no-shows to total visits, P=.002). The major PCP-identified reasons not to treat included: substance abuse (22.5%), patient preference (16%), psychiatric comorbidity (15%), and a delay in specialist input (12%). For 13% of the untreated patients, no reason was identified.

Conclusions: HCV treatment was infrequent in our cohort of outpatients. Barriers to treatment included patient factors (patient preference, alcohol use, missed appointments), provider factors (reluctance to treat past substance abusers), and system factors (referral-associated delays). Multimodal interventions may be required to increase HCV treatment rates.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Frequency of substance abuse among treated (white bars) and untreated patients (shaded bars). EtOH, alcohol abuse; drugs, current abuse of any drug other than alcohol. *P<.05; χ2 test between treated and untreated patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alter M, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–62. - PubMed
    1. Flamm S. Chronic hepatitis c virus infection. JAMA. 2003;289:2413. - PubMed
    1. Fried MW, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82. - PubMed
    1. Lauer G, Walker B. Medical progress: hepatitis c virus infection. N Engl J Med. 2001;345:41. - PubMed
    1. Manns MP, et al. Peginterferon-alpha2b plus ribavirin compared with interferon-alpha2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;348:958–65. - PubMed

Publication types

-